Defence Therapeutics Inc., a prominent biotechnology company known for its advanced endosomal escape technologies, has announced the opening of its first U.S. laboratory in the Boston-Cambridge area. This expansion marks a significant milestone for the company as it establishes its initial physical presence in the United States, aiming to further its research and development efforts in one of the world's leading biotech hubs. The new laboratory, located at Cambridge Scientific Labs in Watertown, will enable Defence Therapeutics to advance and optimize its proprietary Accum® technology for antibody-drug conjugates (ADCs). This move also provides the company with access to premier scientific resources and collaboration opportunities within the region's esteemed biotech ecosystem. Defence Therapeutics views this as a step towards a long-term presence in the dynamic Boston-Cambridge market.